Group B Streptococcus Market
A typical bacterium that is frequently seen in the intestines or lower genital tract is group B strep (streptococcus). In healthy individuals, the bacterium is mostly harmless; but, in neonates, it can result in the deadly sickness known as GBS.
Group B Streptococcus Epidemiology Insights (2022)
- The Total Group B Streptococcus incident cases in the 7MM - ~227K cases in 2022
- EU4 and the UK contributed ~20% of incident cases
- Nearly 2 million pregnant women were estimated to have Group B Streptococcus colonization
- Invasive type account for 22% of incident cases
Group B Streptococcus Epidemiology Segmentation in the 7MM from 2019 to 2040
- Total Incident Cases
- Type-specific Incident Cases
- Age-specific Incident Cases of GBS by types
- Number of Cases of GBS Colonization
Group B Streptococcus Market Insight (2022)
- The Group B Streptococcus Market size in the 7MM was valued ~USD 194 million in 2022
- The United States captured the largest market size for Group B Streptococcus among the 7MM regions
Group B Streptococcus Emerging Drugs and Key Companies
- GBS-NN/NN2: Minervax ApS
- GBS 6 (PF-06760805): Pfizer, and others